Oncoheroes Biosciences has secured worldwide pediatric oncology rights for dovitinib from Novartis
Oncoheroes Biosciences shared a post on LinkedIn:
“As we kick off Childhood Cancer Awareness Month, we’re thrilled to share a major milestone in our fight against childhood cancer!
Oncoheroes Biosciences has secured exclusive worldwide pediatric oncology rights for dovitinib from Novartis. The opportunity to explore this potential option for pediatric cancer treatment marks a significant step forward in our mission to bring new hope to young patients.
With clinical trials on the horizon, we’re eager to investigate how dovitinib can make a difference for children facing bone sarcomas and other challenging pediatric cancers.
Let’s continue to push boundaries and bring innovative treatments to those who need them most.”
Read further.
Source: Oncoheroes Biosciences/LinkedIn
More posts featuring Oncoheroes Biosciences on oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023